Related references
Note: Only part of the references are listed.Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Jacob Grinfeld et al.
HAEMATOLOGICA (2017)
Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms
Jacob Grinfeld et al.
HAEMATOLOGICA (2017)
Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis
Laure Gilles et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Momelotinib inhibits ACVR1/ALK2, decreases hepcidin production, and ameliorates anemia of chronic disease in rodents
Malte Asshoff et al.
BLOOD (2017)
P-Selectin Sustains Extramedullary Hematopoiesis in the Gata1low Model of Myelofibrosis
Gerald J. Spangrude et al.
STEM CELLS (2016)
Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis
Fiorella Ciaffoni et al.
BLOOD CELLS MOLECULES AND DISEASES (2015)
Ribosomopathies: how a common root can cause a tree of pathologies
Nadia Danilova et al.
DISEASE MODELS & MECHANISMS (2015)
Deficiency of the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice by attenuating lineage progression in myelocytes
Noemi A. Zambetti et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
GATA1 and PU.1 Bind to Ribosomal Protein Genes in Erythroid Cells: Implications for Ribosomopathies
Elsa P. Amanatiadou et al.
PLOS ONE (2015)
Deficiency of the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice by attenuating lineage progression in myelocytes
Noemi A. Zambetti et al.
HAEMATOLOGICA (2015)
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
Alessandro M. Vannucchi et al.
HAEMATOLOGICA (2015)
A hyperactive Mpl-based cell growth switch drives macrophage-associated erythropoiesis through an erythroid-megakaryocytic precursor
Eyayu Belay et al.
BLOOD (2015)
Characterization of the TGF-β1 signaling abnormalities in the Gata1low mouse model of myelofibrosis
Maria Zingariello et al.
BLOOD (2013)
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes et al.
BLOOD (2013)
A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis
John Mascarenhas et al.
BLOOD (2013)
Macrophages support pathological erythropoiesis in polycythemia vera and β-thalassemia
Pedro Ramos et al.
NATURE MEDICINE (2013)
Improving Survival Trends in Primary Myelofibrosis: An International Study
Francisco Cervantes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
Ronald F. van Vollenhoven et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Stress erythropoiesis: new signals and new stress progenitor cells
Robert F. Paulson et al.
CURRENT OPINION IN HEMATOLOGY (2011)
Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study
Ayalew Tefferi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Non-Diamond Blackfan Anemia Disorders of Ribosome Function: Shwachman Diamond Syndrome and 5q-Syndrome
Nicholas Burwick et al.
SEMINARS IN HEMATOLOGY (2011)
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
Alfonso Quintas-Cardama et al.
BLOOD (2010)
In vivo efficacy of anti-MPL agonist antibody in promoting primary human hematopoietic cells
Masayuki Kai et al.
BLOOD (2009)
Gata1 expression driven by the alternative HS2 enhancer in the spleen rescues the hematopoietic failure induced by the hypomorphic Gata1low mutation
Anna Rita Migliaccio et al.
BLOOD (2009)
Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics
Ayalew Tefferi et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Increased Differentiation of Dermal Mast Cells in Mice Lacking the Mpl Gene
Barbara Ghinassi et al.
STEM CELLS AND DEVELOPMENT (2009)
JAK2 and MPL mutations in myeloproliferative neoplasms
Priya Koppikar et al.
ACTA HAEMATOLOGICA (2008)
Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1low mouse model of the disease
Anna Rita Migliaccio et al.
EXPERIMENTAL HEMATOLOGY (2008)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)
Thrombopoietin inhibits murine mast cell differentiation
Fabrizio Martelli et al.
STEM CELLS (2008)
Historical review: megakaryopoiesis and thrombopoiesis
Kenneth Kaushansky
BLOOD (2008)
Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche
Hiroki Yoshihara et al.
CELL STEM CELL (2007)
The hypomorphic Gata1low mutation alters the proliferation/differentiation potential of the common megakaryocytic-erythroid progenitor
Barbara Ghinassi et al.
BLOOD (2007)
Differential amplification of murine bipotent megakaryocytic/erythroid progenitor and precursor cells during recovery from acute and chronic erythroid stress
Massimo Sanchez et al.
STEM CELLS (2006)
Variegation of the phenotype induced by the Gatallow mutation in mice of different genetic backgrounds
F Martelli et al.
BLOOD (2005)
The molecular mechanisms that control thrombopoiesis
K Kaushansky
JOURNAL OF CLINICAL INVESTIGATION (2005)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis
AM Vannucchi et al.
AMERICAN JOURNAL OF PATHOLOGY (2005)
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
C James et al.
NATURE (2005)
A gain-of-function mutation of JAK2 in myeloproliferative disorders
R Kralovics et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
RL Levine et al.
CANCER CELL (2005)
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
EJ Baxter et al.
LANCET (2005)
Thrombopoietin induces HOXA9 nuclear transport in immature hematopoietic cells: Potential mechanism by which the hormone favorably affects hematopoietic stem cells
K Kirito et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Development of myelofibrosis in mice genetically impaired for GATA-1low expression (GATA-1low mice)
AM Vannucchi et al.
BLOOD (2002)
p38 MAPK-mediated activation of NF-κB by the RhoGEF domain of Bcr
M Korus et al.
ONCOGENE (2002)
Interleukin-6 stimulates thrombopoiesis through thrombopoietin: role in inflammatory thrombocytosis
A Kaser et al.
BLOOD (2001)
Megakaryocyte c-Mp1 expression in chronic myeloproliferative disorders and the myelodysplastic syndrome: immunoperoxidase staining patterns and clinical correlates
SY Yoon et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2000)
Share Paper
